Liver Transplant Eligibility: Am I a Good Candidate — and When Is the Right Time?

A liver transplant is worth the risk when living with the diseased liver has become more dangerous than the operation. In practice that means decompensated cirrhosis — ascites, confusion, variceal bleeding — or a MELD score of about 15 or more. In India, where most transplants use a living donor, the right time is usually earlier than the waiting-list logic suggests.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai

Patients ask me two opposite questions in the same week. “Doctor, am I sick enough to need a transplant?” And: “Doctor, am I too sick for one?”

Both are the right question. A liver transplant is not a last resort, and it is not the default treatment for every damaged liver. It is a timing decision, and getting the timing wrong in either direction costs patients years.

One thing I want to correct upfront, because it shapes almost everything below: most of what patients read about transplant eligibility online is written for the American deceased-donor system. In India, the large majority of liver transplants are living donor (LDLT) — a family member gives part of their liver. That changes the eligibility conversation substantially. It is not “how sick do you have to be to move up a waiting list”; it is “is transplant the right call, and do you have a donor.” I will flag where that distinction matters. If you have already been declined somewhere and want the evaluation repeated, my post on a second opinion on transplant eligibility covers the documents to bring and how the multidisciplinary assessment runs; this post is about the decision itself. It is educational, not a prescription — your own team has the reports in hand.

The one-line answer

A transplant is worth the risk when living with the diseased liver has become more dangerous than the surgery itself. Everything in an evaluation is an attempt to answer that question honestly — not to sell you on surgery.

Does everyone with cirrhosis need a transplant? No.

Cirrhosis has two clinically distinct phases, and only one of them puts transplant on the table.

Compensated cirrhosis — the liver is scarred but still functioning. Patients are often working, asymptomatic, with no fluid build-up or confusion. This group needs monitoring, not transplant evaluation.

Decompensated cirrhosis — the liver has stopped keeping up. This is the group I actually start evaluating:

• Recurrent ascites (fluid in the abdomen)
• Spontaneous bacterial peritonitis
• Jaundice
• Hepatic encephalopathy (confusion)
• Variceal bleeding
• Worsening kidney function
• Sarcopenia (muscle wasting)
• Repeated hospital admissions for any of the above

The guidelines say the same thing to the referring doctor. The AASLD/AST 2025 candidate-evaluation guideline states that any patient with chronic liver disease who has a decompensating event should be referred for transplant evaluation, and that a MELD score alone should never be a barrier to referral (Strong, Level 4). Its 2013 predecessor set the familiar threshold — a MELD of 15 or more — and the 2025 writing group still considers that a reasonable line in the absence of portal-hypertensive complications, while noting survival benefit on the waiting list from MELD scores above 12. The benefit is not theoretical. In Merion’s analysis of nearly 13,000 American waiting-list patients, deceased-donor transplant cut mortality by 79% overall; at MELD 18–20 the reduction was 38%, and it rose with every point of MELD thereafter. Below MELD 15, recipients actually died more often in the first year than comparable patients who waited. That is the two-edged window in one dataset. My MELD and Child-Pugh explainer covers how the score is built.

Acute-on-chronic liver failure (ACLF) is the other route in, and it runs on a different clock — a patient with known or unknown cirrhosis who turns jaundiced and coagulopathic and develops ascites or confusion within weeks. The AASLD/AST 2025 guideline asks that these patients be considered for referral to a transplant centre (Strong, Level 4). I describe one such patient — a man in his fifties whose wife donated despite a blood-group mismatch — in my post on who should be a living liver donor .

What actually causes the liver disease that leads here

• MASLD (formerly NAFLD, “fatty liver”) — the fastest-growing indication in India right now
• Alcohol-related liver disease
• Chronic hepatitis B and C
• Autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis
• Wilson disease, haemochromatosis, alpha-1 antitrypsin deficiency
• Acute liver failure — days-long deterioration in a previously healthy liver; this one moves fast
• Selected hepatocellular carcinoma (HCC)

How I actually decide — beyond the lab numbers

This is the part that separates a real evaluation from a checklist.

Disease severity numbers matter — bilirubin, INR, creatinine, sodium, albumin, platelets, imaging. But how MELD is actually used changes entirely depending on whether we are considering DDLT or LDLT, and this is where most patient-facing content gets it backwards. In DDLT, MELD dictates allocation — it is “sickest first”, and a high score is what pushes a patient up a deceased-donor waiting list. In LDLT, a living donor is directed specifically to the patient, so MELD is not competing for a spot. It becomes a measure of surgical risk instead. Paradoxically, a lower or moderate MELD is often ideal for LDLT: the patient is stronger, tolerates surgery better, and recovers more smoothly while the partial graft regenerates. Wait too long for MELD to climb, and the patient may become too sick to safely survive an LDLT — the opposite of how the DDLT logic works. This is exactly why early evaluation, long before a patient is critically ill, matters more in the LDLT-majority reality of Indian transplant medicine than it does in a pure allocation-queue system.

Written for an American audience, the 2025 AASLD/AST guideline reaches the same place from the other side: it notes that a survival benefit of living-donor transplantation has been reported in recipients with MELD scores as low as 11, and concludes that “lower MELD score should never be a barrier to referral”. The lower edge of the window still exists — Merion’s data on first-year harm below MELD 15 is a warning against operating on someone who is not yet sick enough — but with a living donor the question becomes “is this patient at the point where the surgery is safest and the benefit real,” not “has the score climbed high enough to win an organ”.

On cancer eligibility specifically: I do not work off a rigid checklist like the Milan criteria alone. Those criteria come from a 1996 Milan study of 48 patients with cirrhosis and small, unresectable HCC — one tumour up to 5 cm, or up to three tumours each 3 cm or less — in whom four-year survival after transplant was 75% overall and 85% when the explanted liver confirmed the tumour was within those limits. Tumour size and number are a starting point, not the whole picture: vascular invasion, response to bridging therapy and overall liver reserve all factor into whether transplant is the right call for a given patient. The AASLD/AST 2025 guideline now treats Milan as “a guide” for listing and for the goal of downstaging, reserves transplant beyond Milan for patients with favourable tumour biology, and asks for an alpha-fetoprotein below 1,000 ng/mL. In Mumbai, the ZTCC liver guideline lists HCC within the broader UCSF criteria, and explicitly allows listing of tumours that have been successfully downstaged into them.

Physical fitness for major surgery — heart, lung, kidney function, nutritional status, frailty, infection status. The 2025 guideline is clear that frailty and body-mass index are risk factors to be measured and treated, not reasons to refuse evaluation.

Psychological and family readiness — lifelong medication adherence is not optional after transplant, and I look for whether a patient and their support system understand that before, not after, listing.

Case: delayed referral, severe alcoholic hepatitis. One of the most heartbreaking patterns I see: patients with severe alcoholic hepatitis reaching a tertiary centre only after multi-organ failure has already set in. By the time they arrive in the ICU, the critical window has closed — infection often rules out standard therapy, and an unstable patient cannot safely undergo transplant evaluation. This pattern disproportionately hits patients in their 30s and 40s with young families, and telling that family we are out of options because the patient arrived too late is one of the hardest conversations in this specialty. The APASL consensus I contributed to puts a number on the window: a “golden window” of about one week before sepsis and extrahepatic organ failure set in, after which “established sepsis/multi-organ failure precludes transplant”. It also says steroid-ineligible patients with severe alcoholic hepatitis should be listed on priority (Grade 1, A) and that transplant “should be offered early in the course of ACLF” (Grade 1, B). Severe alcoholic hepatitis is a medical emergency, not a wait-and-watch diagnosis. Early referral to a specialised liver unit is the decisive factor between a second chance and a preventable outcome.

When you do NOT need a transplant

• Compensated, stable cirrhosis
• Reversible liver injury
• Early fibrosis
• Successfully treated hepatitis
• MASLD without decompensation

Case: recovered without transplant. A young man came in with a first episode of severe alcoholic hepatitis — Maddrey discriminant function above 80, a picture that looked transplant-bound. A sepsis screen was negative. With steroid therapy and aggressive nutritional support he recovered fully, without transplantation. Evaluation is not a pipeline toward surgery. Sometimes the right call is intensive medical management, and a first-episode presentation with good support behind it is exactly where that call gets made.

When transplant isn’t possible yet (not never)

• Active uncontrolled infection
• Ongoing alcohol or substance use
• Severe uncontrolled cardiac disease
• Malignancy outside transplant criteria
• Not currently fit for major surgery

Most of these are reversible with treatment first. This is a “not now”, not a permanent door closing, and I make a point of telling patients that distinction explicitly. The short list of things that genuinely are permanent, and how each reversible one is fixed, is the subject of my companion post on what disqualifies you from a liver transplant .

Living donor vs deceased donor — the part most articles underweight

In India, this is usually the real fork in the road, not MELD-based queue position.

Donor evaluation is its own rigorous process, and the family conversation that goes with it — who is volunteering, whether anyone is being pushed, what the household is taking on — is delicate enough that I have given it its own post: who should be a living liver donor . For the donor’s own operation and recovery, see living liver donor risks and recovery. For the deceased-donor route, the waiting list in India is explained separately, as is the cost and insurance side.

Myths I correct weekly

“I’m too old.” Physiological fitness matters more than age on paper — the 2025 AASLD/AST guideline uses exactly that language, “physiologic age rather than chronologic age”.

“My last blood test looked fine, so I’m off the hook.” Isolated lab values matter less than complications and trajectory. The warning signs of liver damage are clinical before they are biochemical.

“Cancer rules out transplant.” Not automatically — see above.

“Transplant is my last resort.” It is a planned treatment when timed right, not a rescue attempted too late.

Don’t wait until you are critically ill to ask whether you are a candidate. Evaluation does not commit you to surgery — it tells you where you actually stand, and in decompensating liver disease, time is the one resource you cannot get back once it is gone. If you are unsure what to ask when you do go, my list of questions to ask a liver specialist is a reasonable start.

Treating the patient, not just the numbers, is what makes a transplant truly successful. In liver disease, time is our most precious resource — let’s not lose it waiting.

References

1. Dove L, Chadha RM, Lai JC, et al. AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation. Hepatology. 2025;83(6):1609–1645. PMID 41405234. doi:10.1097/HEP.0000000000001644
2. Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144–1165. PMID 24716201. doi:10.1002/hep.26972
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64(2):433–485. PMID 26597456. doi:10.1016/j.jhep.2015.10.006
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol. 2024;81(6):1040–1086. PMID 39487043. doi:10.1016/j.jhep.2024.07.032
5. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant. 2005;5(2):307–313. PMID 15643990. doi:10.1111/j.1600-6143.2004.00703.x
6. Narasimhan G. Living donor liver transplantation in India. Hepatobiliary Surg Nutr. 2016;5(2):127–132. PMID 27115006. doi:10.3978/j.issn.2304-3881.2015.09.01
7. Sarin SK, Choudhury A, Sharma MK, et al (incl. Kalal C). Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update. Hepatol Int. 2019;13(4):353–390. PMID 31172417. doi:10.1007/s12072-019-09946-3
8. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699. PMID 8594428. doi:10.1056/NEJM199603143341104
9. Zonal Transplant Coordination Centre (ZTCC), Mumbai. ZTCC Mumbai Liver Guidelines (Liver Sub-Committee). ztccmumbai.org/liver_guideline_2.pdf (accessed 14 October 2026)